Myriad Genetics MYGN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cancer Care Continuum | $120.2M— | —— | —— | —— | $115.6M— | |
| Mental Health | $38.3M— | —— | —— | —— | $31M-27.1% | |
| Prenatal Health | $41.9M— | —— | —— | —— | $49.3M— | |
| Revenue by Geography | ||||||
| RoW | $13.4M+0.8% | $13.3M-5.0% | $14M-6.0% | $14.9M+4.2% | $14.3M-5.3% | |
| U.S. | $187M-4.8% | $196.5M+2.5% | $191.7M-3.3% | $198.2M+9.1% | $181.6M-7.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Myriad Genetics break its business down?
- Myriad Genetics (MYGN) reports revenue by product across 5 parts — Cancer Care Continuum, Hereditary Cancer, Mental Health, Prenatal Health and Prenatal. Each is extracted from the segment footnotes and tracked over time.
- Where does Myriad Genetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Myriad Genetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
